CXCL16

Across TCGA pan-cancer cohorts, CXCL16 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CXCL16 data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CXCL16 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CXCL16 expression acts as an unfavorable survival marker.

PDAC, LUAD, and CCRCC are the cancer types where CXCL16 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.171	0.535	.011	12	view →
LUAD	DFS	Tertile	All	0.475	0.698	.017	7	view →
CCRCC	OS	Quartile	All	0.436	1.000	.025	1	view →
LSCC	DFS	Median	All	0.505	0.822	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CXCL16–PDAC (OS)

Open the PDAC breakdown →